Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome - Takeaways - MDSpire

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

  • By

  • Yassin A. Bashir

  • Ahmed A. Abdelrheem

  • Maymona Abdelmagid

  • Kaaren K. Reichard

  • Rong He

  • Cinthya J. Zepeda Mendoza

  • Animesh Pardanani

  • Naseema Gangat

  • Ayalew Tefferi

  • January 5, 2026

  • 0 min

Share

  • 1

    Triple-negative primary myelofibrosis (PMF) accounts for 8.5% of chronic phase PMF cases, with a median age of 65 years.

  • 2

    Patients with triple-negative PMF often present with severe anemia (47%) and unfavorable karyotypes (19%).

  • 3

    Independent risk factors for overall survival in triple-negative PMF include age over 65, hemoglobin under 10 g/dL, and leukocyte count over 25 × 10^9/L.

  • 4

    Leukemic transformations occurred in 14% of triple-negative PMF patients, with a median follow-up of 62 months.

  • 5

    High molecular risk mutations negatively impact overall survival and leukemia-free survival in both triple-negative and JAK2-mutated PMF patients.

Original Source(s)

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

  • by Yassin A. Bashir, Ahmed A. Abdelrheem, Maymona Abdelmagid, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

  • January 5, 2026

Related Content

Early detection and correction of preoperative anemia in patients undergoing colorectal surgery—a prospective study

Assessment of Clinical Complications and Treatment Approaches in Non-Transfusion-Dependent α- and β-Thalassemia Patients Compared to Matched Controls: A Retrospective Analysis Utilizing Administrative Claims Data in the United States

Case Report: Atypical hepatobiliary manifestations associated with erythrocyte membrane instability in glucose transporter type 1 deficiency syndrome